HOME >> BIOLOGY >> NEWS
AVAX Technologies receives an additional $3.0 Million (AUD) investment in Australian joint venture from Australian Vaccine Technologies Ltd.

Kansas City, MO, April 6, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced that its Australian joint venture, AVAX Australia Pty. Ltd. has received an additional $3.0 million (AUD) investment from Neptunus International Holdings Limited (NIHL), which was recently renamed Australian Vaccine Technologies Ltd. (AVT). AVAX Australia holds the rights to manufacture and market AVAX Technologies' autologous cancer vaccine (AC Vaccine™) for melanoma, M-Vax™, in Australia and has similar rights in New Zealand. M-Vax is AVAX's lead cancer vaccine and is currently being evaluated in the U.S. in a multicenter pivotal registration trial for Stage III melanoma and in a Phase 2 trial for Stage IV melanoma.

Under the joint venture agreement, AVAX Australia has now received a total of $7.0 million (AUD) from AVT for a 35% interest in the joint venture entity. AVT also has the option to purchase an additional 15% interest for $3.0 million (AUD). Under the terms of the agreement, AVAX Technologies has been granted an option to purchase common stock equivalent to 5% of AVT's fully diluted shares. AVT began trading on the Australian Stock Exchange (ASX) under the symbol "AVT" on March 10, 2000.

Jeffrey M. Jonas, M.D., President and CEO of AVAX Technologies, Inc., stated, "We are very pleased to see AVT increasing their investment in our promising joint venture in Australia. This additional capital investment represents their enthusiasm for the potential of our product and our marketing strategy. We continue to believe that the Australian market allows us to truly demonstrate the validity of our business model and our ability to effectively market individualized product."

In 1999, AVAX announced that it had received notice from Australia's Therapeutic Goods Administration (TGA) that M-Vax may be made available for commercial sale, subject only to licensure of a manufacturing facility. M-Vax, a therapeutic cancer vacc
'"/>

Contact: Olga Fleming
ofleming@cpronline.com
201-641-2408 ext. 34
AVAX Technologies, Inc.
5-Apr-2000


Page: 1 2

Related biology news :

1. Regeneration Technologies introduces advancements at AAOS
2. Palatin Technologies PT-141 increases sexual behavior in female animals
3. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
4. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
5. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
6. AVAX Technologies AC Vaccine™ improves relapse-free survival
7. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
8. First International Congress on Telehealth and Multimedia Technologies Story Ideas
9. Technologies Track, Map Fish Behavior
10. USGS Contributions Enhance Public Health Research, Scientists Showcase Technologies At San Diego Meeting
11. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/25/2019)... (PRWEB) , ... March 25, 2019 , ... ... and Visikol, a contract research organisation focused on advancing drug discovery, have announced ... 3D imaging. , Tissue clearing methods, which are essential to get a better ...
(Date:3/23/2019)... ... March 22, 2019 , ... SeqOnce Biosciences Inc. launches ... preparation. RhinoSeq employs a proprietary kit chemistry that makes it the fastest DNA ... preformatted master mixes for a simple, fast, and stable workflow. The 12-minute library ...
(Date:3/18/2019)... ... March 18, 2019 , ... Periodontal disease, where bacterial infection ... nearly 50% of the US population. Making this disease particularly challenging to treat ... where the cells are enmeshed in a sticky extracellular material that makes them more ...
Breaking Biology News(10 mins):
(Date:4/16/2019)... FREDERICK, Md. (PRWEB) , ... April 16, 2019 ... ... will honor Blue Sources and their project partner, the U.S. Army Center for ... Retransfer of Aquatic Biomonitor Through Combined In-Licensing/Out-Licensing.” , Blue Sources, a veteran-owned company ...
(Date:4/10/2019)... DIEGO (PRWEB) , ... April 10, 2019 , ... After ... kitchen upgrade. The new kitchen is equipped with updated appliances and modern lighting ... company’s La Jolla-based venue. , “We’ve seen tremendous growth in the demand ...
(Date:4/8/2019)... ... ... US Capital Global Securities , an affiliate of US Capital Global, is ... pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of drugs targeted at ... and is ready to begin phase 2b trials. In phase 2a trials, Lorexys had ...
(Date:3/27/2019)... ... March 26, 2019 , ... A leader in the ... services to veterinarians across the United States and Canada since 2004. The primary ... soft tissue injuries in the dog, cat, and horse. Recently, VetStem teamed ...
Breaking Biology Technology:
Cached News: